Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The emerging development of tumor mutational burden in patients with NSCLC.

Future oncology (London, England) - 1 Mar 2020

Zhang Yu, Wang Lifeng, Li Rutian, Liu Baorui

Abstract excerpt

Immunocheckpoint inhibitors (ICIs) which target PD-1 and CTLA-4 have dramatically changed the history of non-small-cell lung cancer treatment. Multiple biomarkers especially tumor mutational burden (TMB) have been raised to be potential predictors of response to ICIs. However, great value of TMB has been observed in patients who receive ICIs monotherapy instead of ICIs combination therapy from latest exploratory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Immunotherapy

Share to Lung Neoplasms

Share to Prognosis

Share to Tumor Microenvironment

Source

Identifiers

PMID: 32048882
DOI: 10.2217/fon-2019-0650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The emerging development of tumor mutational burden in patients with NSCLC.PMID 32048882Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer.Semantic proximity Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

TMB in NSCLC: A Broken Dream?Semantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.